

RECEIVED

DEC 27 2001

TECH CENTER 1600/2900

REMARKS

Claims 1-20 were pending in the present application. In a Response to Restriction Requirement submitted concurrently herewith, Claims 1-9 are elected, with traverse. Upon entry of the Response to Restriction Requirement, claims 10-20 will be withdrawn from consideration. By virtue of this response, claims 1 and 9 have been amended. Accordingly, claims 1-9 are currently under examination.


Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

In the unlikely event that the Fee Transmittal is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 220002057202. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: December 17, 2001

By:


Debra J. Glaister

Registration No. 33,888

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5725
Facsimile: (650) 494-0792

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 1 and 9 have been amended, as follows:

1. (Once amended) An isolated and purified recombinant adenoviral vector, said vector comprising:

an adenoviral genome from which the E1A/E1B genes have been deleted;

a transgene coding for a stress related factor which is a heat shock protein [or the adenosine A3 receptor]; and

a promoter operably linked to said transgene, wherein expression of the transgene is controlled by said promoter.

9. (Once amended) The method of claim 5, wherein said stress related factor is selected from the group consisting of HSP70i, HSP27, HSP40, and HSP60[, and the adenosine A3 receptor].